Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 17 Aug 2018 Planned End Date changed from 14 May 2024 to 27 Sep 2023.
- 17 Aug 2018 Planned primary completion date changed from 14 May 2024 to 27 Sep 2023.